Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, People's Republic of China.
College of Chemical Engineering, Huaqiao University, Xiamen, Fujian 361021, People's Republic of China.
Int J Nanomedicine. 2020 Feb 5;15:675-704. doi: 10.2147/IJN.S226186. eCollection 2020.
With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such as diagnostics, sensing, imaging, and drug delivery. Despite their success in delivering therapeutic agents, several traditional nanocarriers often end up with deprived selectivity and undesired therapeutic outcome, which significantly limit their clinical applicability. Further advancements in terms of improved selectivity to exhibit desired therapeutic outcome toward ablating cancer cells have been predominantly made focusing on the precise entry of nanoparticles into tumor cells via targeting ligands, and subsequent delivery of therapeutic cargo in response to specific biological or external stimuli. However, there is enough room intracellularly, where diverse small-sized nanomaterials can accumulate and significantly exert potentially specific mechanisms of antitumor effects toward activation of precise cancer cell death pathways that can be explored. In this review, we aim to summarize the intracellular pathways of nanoparticles, highlighting the principles and state of their destructive effects in the subcellular structures as well as the current limitations of conventional therapeutic approaches. Next, we give an overview of subcellular performances and the fate of internalized nanoparticles under various organelle circumstances, particularly endosome or lysosome, mitochondria, nucleus, endoplasmic reticulum, and Golgi apparatus, by comprehensively emphasizing the unique mechanisms with a series of interesting reports. Moreover, intracellular transformation of the internalized nanoparticles, prominent outcome and potential affluence of these interdependent subcellular components in cancer therapy are emphasized. Finally, we conclude with perspectives with a focus on the contemporary challenges in their clinical applicability.
随着纳米技术的出现,由于纳米尺寸材料的有利形态、物理化学和功能特性,各种传统治疗策略模式得到了广泛的转变,这些特性在各种生物医学应用中引起了人们的极大兴趣,例如诊断、传感、成像和药物输送。尽管它们在输送治疗剂方面取得了成功,但几种传统的纳米载体往往缺乏选择性和不理想的治疗效果,这极大地限制了它们的临床适用性。为了提高选择性以实现对癌细胞的理想治疗效果,主要通过靶向配体使纳米颗粒精确进入肿瘤细胞,并随后根据特定的生物或外部刺激来输送治疗货物,从而在改进方面取得了进展。然而,细胞内有足够的空间,各种小尺寸的纳米材料可以在其中积累,并通过激活精确的癌细胞死亡途径来显著发挥潜在的特定抗肿瘤作用机制,这是可以探索的。在这篇综述中,我们旨在总结纳米颗粒的细胞内途径,强调其在亚细胞结构中的破坏作用的原理和状态,以及传统治疗方法的当前局限性。接下来,我们概述了各种细胞器情况下(特别是内体或溶酶体、线粒体、细胞核、内质网和高尔基体)内化纳米颗粒的亚细胞性能和命运,通过综合强调一系列有趣的报告中的独特机制来全面强调这些内容。此外,强调了内化纳米颗粒的细胞内转化、这些相互依存的亚细胞成分在癌症治疗中的显著结果和潜在影响。最后,我们以重点关注其临床应用中的当代挑战的观点来进行总结。
Int J Nanomedicine. 2020-2-5
Drug Des Devel Ther. 2013-7-17
Endocr Metab Immune Disord Drug Targets. 2024
Anticancer Drugs. 2011-11
Theranostics. 2017-1-7
Curr Drug Deliv. 2016
Bioact Mater. 2025-3-13
Int J Pharm X. 2024-8-28
Front Pharmacol. 2024-8-23
Int J Nanomedicine. 2024
ACS Biomater Sci Eng. 2017-10-9
ACS Biomater Sci Eng. 2018-3-12
J Mater Chem B. 2016-11-14
Angew Chem Int Ed Engl. 2019-8-30